Stock

Neurogene Inc. NGNE

$33.83-4.25%

All stocks Create account to unlock

Overview

NGNE market data

Price History

NGNE price chart

Valuation & Profitability

no valuation data

No Valuation Data Yet

Alpha Vantage and Twelve Data both returned no valuation metrics for NGNE. Check back after the next daily valuation refresh — this symbol may be new, delisted, or temporarily unavailable from both providers.

Company news

6 captured

8-K filing — Neurogene Inc. (NGNE) · Jul 2, 2026, 12:02 AM

Neurogene Prices $125M Public Offering At $30/Share, $29.999999 Pre‑Funded Warrants · Jul 1, 2026, 11:10 AM

Neurogene Reveals Proposed Public Offering; No Size Disclosed · Jun 30, 2026, 8:05 PM

Neurogene Announces Updated Data From Phase 1/2 Clinical Trial Evaluating NGN-401 Gene Therapy For Treatment Of Females With Rett Syndrome · Jun 29, 2026, 11:25 AM

Neurogene Completes Dosing In Embolden Registrational Trial Of NGN-401, Investigational Gene Therapy Designed To Be One-Time Treatment For Rett Syndrome · Jun 8, 2026, 11:40 AM

Neurogene Q1 EPS $(1.39) Misses $(1.36) Estimate · May 12, 2026, 9:10 PM

Decision & Score

Members

Our Tradable / Watch / Avoid decision and 0–100 conviction score for this symbol are members-only.

Create account to unlock

Trend & Pattern Evidence

Members

Trend alignment and backtested chart-pattern probabilities are members-only.

Create account to unlock

Sector Peer Ranking

Members

Ranked sector peers with scores and decisions are members-only.

Create account to unlock